Drug intelligence / Profile preview

AN0811

Development stage: Unknown
Lead developer: Beijing Anlong Biopharmaceutical
Modality: Small Molecules

Overview

AN0811 is a small molecule antagonist of the interleukin-4 receptor alpha (IL-4Rα), currently under development by Beijing Anlong Biomedical. By targeting IL-4Rα, AN0811 inhibits the signaling pathways of both IL-4 and IL-13, which are key drivers of Type 2 inflammation. This mechanism is analogous to the monoclonal antibody dupilumab but utilizes a small molecule modality, potentially offering advantages in administration or cost. The drug is primarily being investigated for the treatment of atopic dermatitis and asthma.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on AN0811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN0811.

Explore the full profile